Tag: Recce Pharmaceuticals
Recce Pharmaceuticals: Receives ‘intent to grant’ Patent Family 4 for anti-infectives
Recce Pharmaceuticals Receives ‘intent to grant’ Patent Family 4 for anti-infectivesRecce Pharmaceuticals (RCE) receives boost from the Australian...
Recce Pharmaceuticals: Selects CMAX for phase I/II UTI clinical trial
Recce Pharmaceuticals Selects CMAX for phase I/II UTI clinical trialRecce Pharmaceuticals (RCE) selects CMAX Clinical Research in South...
Recce Pharmaceuticals: Advances clinical programs in Q1 FY23
Recce Pharmaceuticals Advances clinical programs in Q1 FY23Recce Pharmaceuticals (RCE) has multiple trials in the pipeline following the...
Recce Pharmaceuticals: Expands and accelerates clinical programs
Recce Pharmaceuticals Expands and accelerates clinical programsRecce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected...
Recce Pharmaceuticals: Makes quarterly progress on R327
Recce Pharmaceuticals: Makes quarterly progress on R327Recce Pharmaceuticals (RCE) progresses clinical trials of its R327 drug candidate during...
Recce Pharmaceuticals: Receives positive safety data from second cohort of Phase I Clinical Trial
Recce Pharmaceuticals Receives positive safety data from second cohort of Phase I Clinical TrialRecce Pharmaceuticals (RCE) has released...
Recce Pharmaceuticals: Secures patent from E.U. regulator
Recce Pharmaceuticals (RCE) has secured a patent from the European regulator covering two of its synthetic anti-infective formulations
...
Recce Pharmaceuticals: Completes $27.95M capital raise
Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million
All up, 21.5 million fully...
Recce Pharmaceuticals: Appoints new CEO
Recce Pharmaceuticals (RCE) Board of Directors has unanimously appointed James Graham as the company’s new CEO
James has...